biosimilar

OneSource Specialty Pharma, a multi-modality specialty pharma CDMO, and Formycon AG (FSE: FYB, Prime Standard, "Formycon"), an…

Zydus Lifesciences, an innovation-led life-sciences company with an international presence has launched the world’s first…

Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…

The product will be manufactured at Lupin’s biotech facility in Pune, which was inspected by the U.S. FDA prior to approval

Dr. Reddy’s Laboratories announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…

Settlement agreement allows Biocon Biologics to commercialise interchangeable aflibercept biosimilar Yesafili in the US; launch…

The approval marks Biocon Biologics’ seventh biosimilar clearance in the US, expanding its oncology portfolio in one of the…

The biosimilar Ustekinumab-kfce is set for commercialisation in the US by February 2025 under a licensing agreement with Janssen

Biocon Biologics' study identifies six policy recommendations to improve access to biosimilars in LMICs, addressing healthcare…

Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases